Actinium Pharmaceuticals Inc (ATNM) Sees Significant Drop in Short Interest
Actinium Pharmaceuticals Inc (NYSE:ATNM) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,469,849 shares, a decrease of 8.5% from the August 31st total of 1,606,358 shares. Based on an average daily trading volume, of 193,919 shares, the short-interest ratio is presently 7.6 days. Approximately 3.4% of the company’s shares are short sold.
Actinium Pharmaceuticals (NYSE:ATNM) opened at 1.35 on Friday. Actinium Pharmaceuticals has a one year low of $1.29 and a one year high of $3.50. The company has a 50-day moving average of $1.70 and a 200 day moving average of $1.81. The firm’s market capitalization is $64.42 million.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Stock Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.